G. Curigliano discusses what antibody drug conjugates (ADCs) are and their mechanism of action in cancer cells. There are currently 2 approved ADCs in oncology/haematology and many trials are currently ongoing accross tumour types. He concludes that this could be the future for cancer treatment, specifically where no identifiable antigen can be targeted by MoAbs.